Ribociclib Improves Overall Survival in HR+/HER2- Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes.

Oncologist · 2022 · PMC8963148 · PMID 35348783

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

All comparisons favored treatment with ribociclib, though some comparisons did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.